// App-Quantinova.ai

: Guselkumab Efficacy and Safety Through 5 Years Among Psoriasis Patients With and Without Metabolic Syndrome at Baseline: Results From VOYAGE 1 and VOYAGE 2

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • Diamant Thaçi

  • Olivia Choi

  • Daphne Chan

  • Ya-Wen Yang

  • Megan Miller

  • Yin You

  • Shu Li

  • Andrew Blauvelt

  • Luis Puig

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • University of Lubeck, Lubeck, Germany

  • Janssen Scientific Affairs, Horsham, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Research and Development, LLC, Spring House, PA

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain

Locations

  • United States

  • Venezuela

  • United Kingdom

  • Maldives

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Endocrine/metabolic Diseases (ME)

  • Dermatology

Disease

  • Metabolic syndrome

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved